COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer (Cypress 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03382912
Recruitment Status : Terminated (The CYPRESS-2 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.)
First Posted : December 26, 2017
Last Update Posted : May 6, 2020
ARMO BioSciences
Information provided by (Responsible Party):
Eli Lilly and Company

Brief Summary:
To compare the efficacy of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with metastatic non-small cell lung cancer as measured by objective response rate.

Condition or disease Intervention/treatment Phase
Non Small Cell Lung Cancer Biological: Pegilodecakin Drug: Nivolumab Phase 2

Detailed Description:
This is an open-label, multi-center, randomized, Phase 2 study designed to compare the efficacy and safety of pegilodecakin in combination with nivolumab versus nivolumab alone in participants with stage IV / metastatic wild type non-small cell lung cancer and tumors with low tumor expression of PD-L1 (0-49%).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 52 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Phase 2 Trial of AM0010 in Combination With Nivolumab vs. Nivolumab Alone as Second-Line Therapy in Subjects With Stage IV / Metastatic Wild Type Non-Small Cell Lung Cancer and Low Tumor Expression of PD-L1
Actual Study Start Date : March 22, 2018
Actual Primary Completion Date : August 28, 2019
Actual Study Completion Date : February 11, 2020

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: 1
Pegilodecakin self-administered as a SQ injection QD (≤ 80kg body weight = 0.8mg or [0.2mL] > 80kg body weight = 1.6mg [0.4mL]). Nivolumab will be administered as intravenous (IV) infusion on Day 1 of a 14-day cycle (240mg over 30 minutes (± 10min))
Biological: Pegilodecakin
Pegilodecakin plus Nivolumab
Other Names:
  • LY3500518
  • AM0010

Drug: Nivolumab
Nivolumab Alone

Active Comparator: 2
Nivolumab will be administered as an intravenous (IV) infusion on Day 1 of a 14-day cycle (240mg over 30 minutes (± 10min))
Drug: Nivolumab
Nivolumab Alone

Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: 36 months after the last participant randomized ]
    The primary endpoint of this study is ORR defined as the proportion of participants who achieve a CR or PR as assessed by RECIST v.1.1.

Secondary Outcome Measures :
  1. Overall Survival [ Time Frame: 36 months after the last participant randomized ]
    OS defined as the time from date of randomization to death due to any cause

  2. Progression Free Survival [ Time Frame: 36 months after the last participant randomized ]
    PFS defined as the time from date of randomization to the earlier of first documentation of disease progression or death due to any cause

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Participants must have histologically or cytologically confirmed WT NSCLC that is stage IV / metastatic or recurrent
  2. Participants must have received at least one prior systemic therapy that was not an anti-PD-1, anti-PD-L1 and/or anti-CTLA-4 treatment for the advanced stage of the disease
  3. Participants with tumor tissue low expression of PD-L1 as defined by Tumor Proportion Score (TPS) 0% - 49%
  4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  5. Participants with measurable disease by spiral computed tomography (CT) or magnetic resonance imaging (MRI) per Response Evaluation Criteria in Solid Tumor (RECIST) v.1.1 criteria
  6. Participants that have completed prior radiotherapy or radiosurgery at least 2 weeks prior to randomization

Exclusion Criteria:

  1. Participants with active central nervous system (CNS) metastases or carcinomatous meningitis
  2. Participants with any serious or uncontrolled medical disorder or active infection with the hepatitis virus or the human immunodeficiency virus (HIV)
  3. Participants with Grade 1 (NCI-CTCAE v.4.03) toxicities attributed to prior anti-cancer therapy (other than alopecia and fatigue) prior to randomization
  4. Participants that have received nivolumab
  5. Participants that have received therapy with anti-tumor vaccines or other immuno-stimulatory antitumor agents
  6. Participants with a history of severe hypersensitivity reactions to monoclonal antibodies
  7. Participants that have received therapy with anti-PD-1, anti-PD-L1, anti-PD-L-2, anti-CD-137, and/or anti CTLA-4 antibodies
  8. Participants receiving any investigational agent within 28 days of first administration of trial treatment
  9. Pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03382912

Show Show 35 study locations
Sponsors and Collaborators
Eli Lilly and Company
ARMO BioSciences
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Layout table for additonal information
Responsible Party: Eli Lilly and Company Identifier: NCT03382912    
Other Study ID Numbers: 17161
J1L-AM-JZGD ( Other Identifier: Eli Lilly and Company )
AM0010-202 ( Other Identifier: ARMO BioSciences )
First Posted: December 26, 2017    Key Record Dates
Last Update Posted: May 6, 2020
Last Verified: May 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:


Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms
Antineoplastic Agents, Immunological
Antineoplastic Agents